Skip to main content
Top
Published in: Annals of Surgical Oncology 11/2012

01-10-2012 | Gynecologic Oncology

Systematic Pelvic and Aortic Lymphadenectomy in Advanced Ovarian Cancer Patients at the Time of Interval Debulking Surgery: A Double-Institution Case–Control Study

Authors: Anna Fagotti, MD, PhD, Pierandrea De Iaco, MD, Francesco Fanfani, MD, Giuseppe Vizzielli, MD, Federica Perelli, MD, Federica Pozzati, MD, Anna Myriam Perrone, MD, Luigi Carlo Turco, MD, Giovanni Scambia, MD

Published in: Annals of Surgical Oncology | Issue 11/2012

Login to get access

Abstract

Background

The prognostic role of systematic lymphadenectomy remains unclear in advanced ovarian cancer (AOC). Only few retrospective case series have investigated the percentage of lymph node metastases after neoadjuvant chemotherapy. This multi-institutional case-control study analyzed the prognostic role of systematic lymphadenectomy in AOC patients at the time of interval debulking surgery (IDS).

Methods

From January 2005 to December 2010, the records of patients with AOC admitted to IDS at the Catholic University of Rome (n = 101, controls) and at the University of Bologna (n = 50, cases) were retrospectively analyzed. The cases, routinely submitted to systematic pelvic and aortic lymphadenectomy, were matched 1:2 with the controls, who did not routinely undergo lymphadenectomy. To correctly assess the prognostic role of lymphadenectomy, only patients with optimally debulked disease were included. Progression-free survival and overall survival were analyzed by a log-rank test.

Results

After an overall mean follow-up of 36 months (95 % confidence interval 33–39), 35 and 63 recurrences (70.0 vs. 62.4 %; p = NS) and 15 and 24 deaths due to disease (30 vs. 23.7 %; p = NS) were observed in the case and controls, respectively. The 2-year progression-free survival rate was 36 versus 25 % (p = 0.834), and the 2-year overall survival rate was 69 versus 88 % (p = 0.777), in the case and controls, respectively. The median operating time was longer, and the percentage of patients requiring blood transfusions was higher in the cases than in the controls (225 vs. 210 min, p = 0.023, and 54 vs. 22.8 %, p = 0.0001, respectively).

Conclusions

Lymphadenectomy at the time of IDS could be omitted, at least in high-risk patients.
Appendix
Available only for authorised users
Literature
2.
go back to reference Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560–6.PubMedCrossRef Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560–6.PubMedCrossRef
3.
go back to reference Eisenkop SM, Freiedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–8.PubMedCrossRef Eisenkop SM, Freiedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–8.PubMedCrossRef
4.
go back to reference Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16:585–96.PubMedCrossRef Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16:585–96.PubMedCrossRef
5.
go back to reference Ozols RF. Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol. 2000;27:47–9.PubMed Ozols RF. Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol. 2000;27:47–9.PubMed
6.
go back to reference Van Der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995;332:629–34.PubMedCrossRef Van Der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995;332:629–34.PubMedCrossRef
7.
go back to reference Chambers SK. Systematic lymphadenectomy in advanced epithelial ovarian cancer: two decades of uncertainty resolved. J Natl Cancer Inst. 2005;97:548–9.PubMedCrossRef Chambers SK. Systematic lymphadenectomy in advanced epithelial ovarian cancer: two decades of uncertainty resolved. J Natl Cancer Inst. 2005;97:548–9.PubMedCrossRef
8.
go back to reference Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238–44.PubMedCrossRef Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238–44.PubMedCrossRef
10.
go back to reference Du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733–9.PubMedCrossRef Du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733–9.PubMedCrossRef
11.
go back to reference Rouzier R, Bergzoll C, Brun JL, et al. The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database. BJOG. 2010;117:1451–8.PubMedCrossRef Rouzier R, Bergzoll C, Brun JL, et al. The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database. BJOG. 2010;117:1451–8.PubMedCrossRef
12.
go back to reference Joulie F, Morice P, Rey A, et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Comparative study of initial lymphadenectomy or after chemotherapy. Gynecol Obstet Fertil. 2004;32:502–7.PubMedCrossRef Joulie F, Morice P, Rey A, et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Comparative study of initial lymphadenectomy or after chemotherapy. Gynecol Obstet Fertil. 2004;32:502–7.PubMedCrossRef
13.
go back to reference Eisenhauer EA, Therasseb P, Bogaertsc J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef Eisenhauer EA, Therasseb P, Bogaertsc J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
14.
go back to reference Gronlund B, Hansen HH, Høgdall C, Høgdall EV, Engelholm SA. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? Br J Cancer. 2004;90:377–82.PubMedCrossRef Gronlund B, Hansen HH, Høgdall C, Høgdall EV, Engelholm SA. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? Br J Cancer. 2004;90:377–82.PubMedCrossRef
15.
go back to reference Sharma S, Driscoll D, Oduns K, Venkatadri A, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193:2077–82.PubMedCrossRef Sharma S, Driscoll D, Oduns K, Venkatadri A, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193:2077–82.PubMedCrossRef
16.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.PubMedCrossRef
17.
go back to reference Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433–43.PubMedCrossRef Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433–43.PubMedCrossRef
18.
go back to reference Rose PG, Nerenstone S, Brady MF, et al; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489–97.PubMedCrossRef Rose PG, Nerenstone S, Brady MF, et al; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489–97.PubMedCrossRef
19.
go back to reference Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.PubMedCrossRef Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.PubMedCrossRef
20.
go back to reference Di Re F, Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol. 1996;62:360–5.PubMedCrossRef Di Re F, Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol. 1996;62:360–5.PubMedCrossRef
21.
go back to reference Baiocchi G, Grosso G, di Re E, Fontanelli R, Raspagliesi F, di Re F. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. Gynecol Oncol. 1998;69:151–6.PubMedCrossRef Baiocchi G, Grosso G, di Re E, Fontanelli R, Raspagliesi F, di Re F. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. Gynecol Oncol. 1998;69:151–6.PubMedCrossRef
22.
go back to reference Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol. 1995;56:328–37.PubMedCrossRef Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol. 1995;56:328–37.PubMedCrossRef
23.
go back to reference Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40:103–6.PubMedCrossRef Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40:103–6.PubMedCrossRef
24.
go back to reference Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99–106.PubMedCrossRef Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99–106.PubMedCrossRef
Metadata
Title
Systematic Pelvic and Aortic Lymphadenectomy in Advanced Ovarian Cancer Patients at the Time of Interval Debulking Surgery: A Double-Institution Case–Control Study
Authors
Anna Fagotti, MD, PhD
Pierandrea De Iaco, MD
Francesco Fanfani, MD
Giuseppe Vizzielli, MD
Federica Perelli, MD
Federica Pozzati, MD
Anna Myriam Perrone, MD
Luigi Carlo Turco, MD
Giovanni Scambia, MD
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2400-9

Other articles of this Issue 11/2012

Annals of Surgical Oncology 11/2012 Go to the issue

Hepatobiliary Tumors

Upper Transversal Hepatectomy